EUVIMEDScopri EUVIMED
Übersichtsarbeit

A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis

Anthony Thompson, Adriana Morales-Rivera, Emily Patel, Alec Sevilla, Collins Langley, Jay Wolverton

Journal of Drugs in Dermatology · 2026

DOI: 10.36849/jdd.9507 ↗

At a glance

Übersichtsarbeit in Journal of Drugs in Dermatology, 2026. Written by Anthony Thompson and 5 co-authors. Major MEDLINE topics: Dermatitis, Seborrheic, Off-Label Use, Dermatologic Agents.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

BACKGROUND: Seborrheic dermatitis (SD) is a chronic inflammatory skin condition driven by overactive sebaceous glands, Malassezia colonization, immune dysfunction, and epidermal barrier disruption. While topical corticosteroids and antifungals are first-line treatments, rebound disease and adverse effects limit long-term use. OBJECTIVE: To evaluate seven off-label therapies for SD: topical calcineurin inhibitors (TCI), metronidazole, phosphodiesterase-4 inhibitors (PDE4), systemic antifungals, isotretinoin, natural remedies, and microbiome-directed therapies. METHODS: A PubMed-based narrative review included clinical trials, observational studies, and case reports when higher-level data were lacking. RESULTS: TCIs and PDE4 inhibitors demonstrated consistent efficacy for facial SD as steroid-sparing options. Metronidazole provided modest benefit, mainly in patients with concomitant rosacea. Both systemic antifungals and low-dose isotretinoin were effective for moderate-to-severe disease, though systemic therapy requires monitoring for hepatotoxicity. Natural agents (eg, honey, tea tree oil) and microbiome-targeted therapies (eg, probiotics, Triphala) showed variable improvement. CONCLUSION: These therapies serve as promising treatment options for SD, particularly in refractory cases or when standard treatments are unsuitable. Larger comparative trials with standardized outcomes and long-term follow-up are needed to clarify their role.

Subjects

MeSH terms (MEDLINE)

Dermatitis, SeborrheicOff-Label UseDermatologic AgentsHumansAntifungal AgentsPhosphodiesterase 4 InhibitorsCalcineurin InhibitorsIsotretinoinTreatment Outcome

Substances

Antifungal AgentsDermatologic AgentsPhosphodiesterase 4 InhibitorsCalcineurin InhibitorsIsotretinoin

Cite

APA

Thompson, A., Morales-Rivera, A., Patel, E., Sevilla, A., Langley, C., & Wolverton, J. (2026). A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis. Journal of Drugs in Dermatology. https://doi.org/10.36849/jdd.9507

Vancouver

Thompson A, Morales-Rivera A, Patel E, Sevilla A, Langley C, Wolverton J. A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis. Journal of Drugs in Dermatology. 2026. doi:10.36849/jdd.9507

BibTeX
@article{Thompson2026,
  author = {Thompson, Anthony and Morales-Rivera, Adriana and Patel, Emily and Sevilla, Alec and Langley, Collins and Wolverton, Jay},
  title = {A Narrative Review of Seven Off-Label Treatment Options for Seborrheic Dermatitis},
  journal = {Journal of Drugs in Dermatology},
  year = {2026},
  doi = {10.36849/jdd.9507}
}
Start for free →